Bydureon type 2 diabetes drug not yet authorized by FDA

Bydureon will not yet be approved for use in the United States industry, according to the FDA. Bydreon is a “reformulation” of the already-approved Byetta. The FDA has said that they need more data on the possible consequences on heart rates. When the FDA released their statement on this drug, stocks of Eli Lilly dropped like a rock. Competitor’s shares really increased.

How you are able to use Bydureon

Bydureon is the brand new extended-release injection drug meant to help treat Diabetes type 2. The drug uses a lot of an exenatide drug. This is Byetta which is on the industry and manufactured through Eli Lilly. Individuals with non-insulin dependent diabetes can more easily process glucose helping blood sugar amounts with this drug. Byetta is just like all the other drugs Diabetes type 2 is controlled with. Of course, correct diet and exercise would be almost as effective as the drugs. Controlling food intake and becoming physically healthy with exercise will do one of the most for those with Diabetes type 2 although drugs can help.

Hazards of Bydureon

Byetta and Bydureon are alike. Potential risks are associated with both. Two more studies on the effect of Bydureon on heart rates are what the FDA is requiring be done. Byetta has a bunch of known things associated with it. These consist of changes in behavior and mood, headaches, dizziness and clumsy movements. Bydureon, as an extended-release dose of the very same drug, could have stronger potential side effects.

Bydureon changes prices on stock

The FDA was expected by Eli Lilly investors to rule earlier this year on Bydureon. The two studies requested by the FDA will delay the decision until the middle of 2012. Eli Lilly has been pushing very aggressive sales goals for Bydureon – more than $1 billion per year. The delay is bad for the business. It means rivals can catch up fast. Eli Lilly is preparing for Bydureon to be its only major product launch in the next three years. With major drug patents have been expiring, the business has been facing serious declines in profit and stock prices.

Citations

Drugs.com

drugs.com/byetta.html

IBJ.com

ibj.com/fda-demands-more-tests-on-new-lilly-diabetes-drug/PARAMS/article/22930

Reuters

reuters.com/article/idUSTRE69J28R20101020?utm_source=feedburner and utm_medium=feed and utm_campaign=Feed: reuters/businessNews (News / US / Business News) and utm_content=Google Feedfetcher